BLFS (BioLife Solutions) Cyclically Adjusted Revenue per Share: $1.86 (As of Mar. 2026)


BLFS BioLife Solutions Inc BLFS
72 GF Score
Price $28.24
GF Value $28.64
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions Cyclically Adjusted Revenue per Share?

BioLife Solutions BLFS -0.21% 72 Cyclically Adjusted Revenue per Share is $1.86 as of Mar. 2026. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.64 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioLife Solutions's adjusted revenue per share for the three months ended in Mar. 2026 was $0.558. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.86 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BioLife Solutions's average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioLife Solutions was 17.80% per year. The lowest was -31.70% per year. And the median was 3.05% per year.

As of today (2026-07-01), BioLife Solutions's current stock price is $28.24. BioLife Solutions's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.86. BioLife Solutions's Cyclically Adjusted PS Ratio of today is 15.18.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioLife Solutions was 44.47. The lowest was 2.16. And the median was 14.11.


BioLife Solutions  (NAS:BLFS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioLife Solutions's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=28.24/1.86
=15.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioLife Solutions was 44.47. The lowest was 2.16. And the median was 14.11.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioLife Solutions Cyclically Adjusted Revenue per Share Related Terms


BioLife Solutions Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioLife Solutions's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions Cyclically Adjusted Revenue per Share Chart

BioLife Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.39 1.52 1.52 1.63 1.79

BioLife Solutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 1.73 1.78 1.79 1.86

BLFS vs STAA, ATRC, KMTS: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Cyclically Adjusted PS Ratio falls into.


BLFS
72GF Score
BioLife Solutions Inc BLFS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLife Solutions Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioLife Solutions's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.558/330.2130*330.2130
=0.558

Current CPI (Mar. 2026) = 330.2130.

BioLife Solutions Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.158 241.018 0.216
201609 0.168 241.428 0.230
201612 0.175 241.432 0.239
201703 0.182 243.801 0.247
201706 0.195 244.955 0.263
201709 0.224 246.819 0.300
201712 0.228 246.524 0.305
201803 0.271 249.554 0.359
201806 0.254 251.989 0.333
201809 0.224 252.439 0.293
201812 0.294 251.233 0.386
201903 0.309 254.202 0.401
201906 0.273 256.143 0.352
201909 0.261 256.759 0.336
201912 0.402 256.974 0.517
202003 0.579 258.115 0.741
202006 0.426 257.797 0.546
202009 0.356 260.280 0.452
202012 0.447 260.474 0.567
202103 0.507 264.877 0.632
202106 0.773 271.696 0.939
202109 0.781 274.310 0.940
202112 0.647 278.802 0.766
202203 0.862 287.504 0.990
202206 0.955 296.311 1.064
202209 0.955 296.808 1.062
202212 -0.914 296.797 -1.017
202303 0.876 301.836 0.958
202306 0.673 305.109 0.728
202309 0.541 307.789 0.580
202312 -0.312 306.746 -0.336
202403 0.406 312.332 0.429
202406 0.429 314.175 0.451
202409 0.463 315.301 0.485
202412 0.324 315.605 0.339
202503 0.456 319.799 0.471
202506 0.532 322.561 0.545
202509 0.576 324.800 0.586
202512 0.363 324.054 0.370
202603 0.558 330.213 0.558

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.86 mean?
BioLife Solutions (BLFS) has a Cyclically Adjusted Revenue per Share of $1.86 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioLife Solutions and its competitors.
Is BioLife Solutions' Cyclically Adjusted Revenue per Share too high?
BioLife Solutions' current Cyclically Adjusted Revenue per Share is $1.86. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Cyclically Adjusted Revenue per Share compare to STAA and ATRC?
BioLife Solutions' Cyclically Adjusted Revenue per Share of $1.86 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioLife Solutions and its competitors. BioLife Solutions's current Cyclically Adjusted Revenue per Share is $1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.64, compared to a current price of $28.24 — trading 1.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.86. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Cyclically Adjusted Revenue per Share is $1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be undervalued. The current stock price of $28.24 is trading 1.4% below its estimated GF Value™ of $28.64. GuruFocus considers BioLife Solutions to be Fairly Valued.

Key valuation signals for BLFS:

  • Cyclically Adjusted Revenue per Share: $1.86
  • GF Value™: $28.64 vs. price of $28.24 (1.4% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioLife Solutions Business Description

Other Exchanges BJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score

Get the complete analysis for BLFS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.24
Price
$28.64
GF Value